Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2020 | Changing treatment landscape of relapsed/refractory myeloma

Joshua Richter • 17 Sep 2020
SOHO 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib Iberdomide Lenalidomide Pomalidomide
DREAMM-2 DREAMM-6

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, outlines the changing treatment landscape for patients with relapsed/refractory multiple myeloma including the approval of belantamab mafodotin, a BCMA targeting antibody-drug conjugate, as well as melflufen, evaluated in the HORIZON (NCT02963493) and OCEAN (NCT03151811) trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Richter

The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM 1:43
The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
Joshua Richter • 19 Sep 2025
How does linvoseltamab compare with other bispecific antibodies in multiple myeloma? 1:34
How does linvoseltamab compare with other bispecific antibodies in multiple myeloma?
Joshua Richter • 19 Sep 2025
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma 3:04
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma
Joshua Richter • 4 Mar 2025
What lies ahead for bispecifics in multiple myeloma? 2:02
What lies ahead for bispecifics in multiple myeloma?
Joshua Richter • 4 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals